Welcome to our dedicated page for Adapthealth SEC filings (Ticker: AHCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AdaptHealth Corp. filings document the company’s healthcare-at-home operations, financial reporting and public-company governance. Its Form 8-K disclosures include quarterly and annual earnings releases, Regulation FD updates, financial guidance, business highlights and material events related to operating partnerships, asset dispositions and executive leadership changes.
The filing record also covers capital structure and financing matters, including credit agreements entered into by AdaptHealth LLC and related guarantees, collateral and borrowing commitments. AdaptHealth’s proxy materials describe board and executive compensation matters, while its securities disclosures identify common stock trading under AHCO on the Nasdaq Stock Market.
AdaptHealth Corp. Chief Commercial Officer Russell E. Schuster III sold 11,275 shares of Common Stock on June 1, 2026 at $10.06 per share in an open-market transaction. The sale occurred automatically under a Rule 10b5-1 trading plan adopted on March 2, 2026.
After this transaction, he directly holds 136,538 shares of AdaptHealth Common Stock, indicating that the sale represents only a portion of his overall stake.
AdaptHealth Corp. filed an amended report to correct the Date of Report for its earlier disclosure about appointing Daniel McFadden as Chief Operating Officer and to add his final compensation terms. The board’s compensation committee raised his annual base salary from $410,000 to $550,000, retroactive to the May 4, 2026 appointment date, and kept his target annual bonus at 100% of base salary, pro-rated for 2026. He also received a one-time restricted stock unit grant valued at $464,110, with half vesting annually over three years and half vesting between 0% and 200% based on relative total shareholder return over a three-year performance period beginning on February 1, 2026.
AdaptHealth Corp. reported that Chief Operating Officer Daniel Edward McFadden received an equity award in the form of restricted stock units. On the transaction date, he acquired 20,134 shares of Common Stock at no cash cost as a grant, increasing his direct holdings to 103,376 shares after the award. The footnote explains that these shares are restricted stock units that will be settled in common stock when they vest, meaning he does not receive all shares immediately but over time as vesting conditions are met.
AdaptHealth Corp. reported first quarter 2026 results with net revenue of $819.8 million, up 5.4% from $777.9 million a year earlier, and organic revenue growth of 9.1% across all segments. Net loss attributable to AdaptHealth widened to $16.0 million, and Adjusted EBITDA declined to $121.2 million from $127.9 million.
Free cash flow was negative $27.5 million, compared with essentially breakeven a year ago, as the company increased investment in equipment and acquisitions. Management highlighted completing a major de novo expansion tied to a new strategic partner and growing digital patient engagement to 412,000 registered myApp users.
AdaptHealth raised its 2026 net revenue outlook to a range of $3.45 billion to $3.52 billion while maintaining Adjusted EBITDA and free cash flow guidance. Separately, the company terminated Chief Operating Officer Toby Scott Barnhart and appointed Daniel McFadden, previously Chief Business Systems Officer, as the new COO.
AdaptHealth Corp. reported first quarter 2026 results with net revenue of $819.8 million, up 5.4% from $777.9 million a year earlier, and organic revenue growth of 9.1% across all segments. Net loss attributable to AdaptHealth widened to $16.0 million, and Adjusted EBITDA declined to $121.2 million from $127.9 million.
Free cash flow was negative $27.5 million, compared with essentially breakeven a year ago, as the company increased investment in equipment and acquisitions. Management highlighted completing a major de novo expansion tied to a new strategic partner and growing digital patient engagement to 412,000 registered myApp users.
AdaptHealth raised its 2026 net revenue outlook to a range of $3.45 billion to $3.52 billion while maintaining Adjusted EBITDA and free cash flow guidance. Separately, the company terminated Chief Operating Officer Toby Scott Barnhart and appointed Daniel McFadden, previously Chief Business Systems Officer, as the new COO.
AdaptHealth Corp. Chief Technology Officer Albert A. Prast filed an amended Form 4 to correct his reported share ownership. The amendment re-reports a prior tax-withholding disposition of 58,203 shares of common stock at $10.33 per share used to cover tax obligations, not an open-market sale. After reflecting this correction and prior filings that overstated his holdings by 135,443 shares, Prast is shown as beneficially owning 338,712 shares of common stock directly.
AdaptHealth Corp. is asking stockholders to vote at its June 18, 2026 virtual annual meeting on three items: electing nine directors for one-year terms, ratifying KPMG LLP as auditor for 2026, and approving a non-binding say-on-pay resolution for 2025 executive compensation.
Stockholders of record on April 24, 2026, when 136,054,152 common shares were outstanding, may vote online, by phone, mail or during the webcast. The proxy also details board independence, committee structures, auditor fees, and a pay-for-performance program built around 2025 Net Revenue of $3.24 billion, Adjusted EBITDA of $616.7 million, and Free Cash Flow of $219.4 million.
AdaptHealth Corp. entered into a new senior secured credit facility totaling $1.1 billion, replacing its prior credit arrangements and extending its debt maturity profile. The package includes a $325 million Term Loan A, a $325 million delayed draw term loan, and a $450 million revolving credit facility.
Proceeds from the new term loan repaid the existing term loan and prior credit agreement, while the delayed draw facility is intended to redeem the 6.125% Senior Notes due 2028, lowering interest expense. The facility, maturing in April 2031, features lower SOFR-based pricing tied to leverage covenants and is supported by recent credit rating upgrades. The company states the transaction does not change its full-year 2026 guidance.